Brazilian Portuguese version of EmPHasis-10 for pulmonary hypertension
Official title: Cultural Adaptation, Validation, and Reliability of the EMPHASIS-10 Questionnaire for Assessing Quality of Life in Patients With Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Brazilian Version
Run by Hospital de Clinicas de Porto Alegre · NCT07822997 · Data updated 2026-11-12
This study tests a Brazilian Portuguese version of the EmPHasis-10 questionnaire to see if it reliably measures quality of life in adults with pulmonary hypertension in Porto Alegre, Brazil.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Hospital de Clinicas de Porto Alegre Academic / other |
| Locations | 1 site (Porto Alegre) |
| Status | Recruiting |
| Started | March 1, 2026 |
| Main results expected | March 2027 |
| Study ends | July 2027 |
| Registry record updated | September 16, 2026 |
| Trial ID | NCT07822997 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) with confirmed PAH (group 1) or CTEPH (group 4), native Brazilian Portuguese speakers, clinically stable for at least 3 months, and able to provide informed consent.
✕Probably not a fit
Patients not meeting language, diagnostic, or stability criteria may not benefit from this validation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a cross-sectional observational study to translate, culturally adapt, and validate the EmPHasis-10 quality-of-life questionnaire for Brazilian patients with precapillary pulmonary hypertension (PAH and CTEPH). The process includes forward translations, back-translation, expert review, pilot testing, and final adjustments guided by PHA-UK guidelines. Fifty adult patients will be recruited from the Pulmonary Circulation Outpatient Clinic at Hospital de Clínicas de Porto Alegre, with inclusion criteria focusing on native Brazilian Portuguese speakers who are clinically stable and on confirmed diagnoses. The study aims to establish the Brazilian Portuguese version's reliability, validity, and comprehension to support local risk stratification and patient-centered care.
Why it matters
Potential benefit: If successful, clinicians in Brazil will have a validated, easy-to-use QoL tool to help monitor and manage patients with pulmonary hypertension.
How similar studies have gone: Prior studies in other languages have shown EmPHasis-10 to correlate well with clinical outcomes across PH populations, supporting cross-cultural validation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Willingness to participate in the study after being informed and having provided written informed consent; * Age ≥ 18 years; * Diagnosis of precapillary pulmonary hypertension from groups 1 and 4, confirmed by right heart catheterization; * Clinically stable patients with no changes in therapy for at least 3 months; * Native speaker of Brazilian Portuguese; * Literate patient. Exclusion Criteria: * Diagnosis of pulmonary hypertension from groups 2, 3, and/or 5; * Spirometry showing forced vital capacity (FVC) ≤ 70% predicted and/or forced expiratory volume in the first second (FEV₁) ≤ 60% predicted; * Severe communication impairment, including major cognitive deficit or severe hearing or visual impairment, resulting in inability to respond to the questionnaires or to understand the study procedures; * Patients who experience clinical exacerbation or worsening between the days on which the questionnaires are administered; * Refusal to participate in the study.
Where it's running
-
Hospital de Clínicas de Porto Alegre
Porto Alegre, Brazil Recruiting
Study contacts
- Principal investigator: Marcelo B Gazzana, MD, PhD — Hospital de Clinicas de Porto Alegre
- Study coordinator: Bruna H Bianchini, MD
- Email: bhbianchini@hcpa.edu.br
- Phone: 55+ 48 991023563
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Levosimendan to see if it helps the heart after PEA in CTEPH
This small randomized trial tests whether giving levosimendan around surgery helps reduce pulmonary artery pressure and support right heart function after pulmonary endarterectomy for CTEPH.
-
Early treatment with inhaled treprostinil for exercise-induced pulmonary hypertension in ILD or CTD
This study tests whether inhaled treprostinil added to standard care can improve exercise-related lung blood flow and function in adults with ILD or CTD who develop pulmonary hypertension during exercise.
-
Inhaled mosliciguat for pulmonary hypertension in interstitial lung disease (PH-ILD) patients
This study tests inhaled mosliciguat versus placebo in people with PH-ILD to see if it helps with their condition.
-
Pulmonary Artery Denervation for Pulmonary Hypertension After M-TEER
This study tests whether PADN can help people with pulmonary hypertension after M-TEER compared with standard medical therapy.
-
Risk Factor Assessment for Acute Pulmonary Hypertension Crisis
This study tests how to identify people with pulmonary hypertension who are at risk of a sudden, life-threatening crisis.
-
PH Biorepository for Translational Research
This project collects blood samples and health information from adults with or suspected to have pulmonary hypertension to build a biorepository for future biomarker research.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.